

香港聯合交易所有限公司  
(香港交易及結算所有限公司全資附屬公司)

THE STOCK EXCHANGE OF HONG KONG LIMITED  
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

## 通告 CIRCULAR

事項： 修訂上交所上市中華通證券名單  
Subject: **Change of SSE-Listed China Connect Securities List**  
查詢： 參與者一般查詢熱線<sup>1</sup> (電話：2840 3626 電子郵箱：[trd@hkex.com.hk](mailto:trd@hkex.com.hk))  
Enquiry: **Participant General Enquiry Hotline<sup>1</sup> (Tel : 2840 3626 E-mail : [trd@hkex.com.hk](mailto:trd@hkex.com.hk))**

由 **2019 年 9 月 3 日起**，上海證券交易所上市的輔仁藥業（上交所證券代碼：600781）將從中華通證券名單中移除並加入到中華通特別證券名單，即只可經滬股通賣出。中華通證券（可買入及賣出）名單的總數將會是 579 隻，而中華通特別證券（只可賣出）名單的總數將會是 307 隻。上述修訂可在互聯互通市場網頁的「[合資格股份](#)」部分查閱。

**With effect from 3 September 2019**, FUREN GROUP PHARMACEUTICAL (SSE Security code: 600781) listed on Shanghai Stock Exchange will be removed from the list of China Connect Securities and will be added to the list of Special China Connect Securities which will be eligible for sell only in Northbound trading. The total number of China Connect Securities (both buy and sell) will be 579 while total number of Special China Connect Securities (sell only) will be 307. The aforementioned change is also available on the "[Eligible Stocks](#)" section of the Mutual Market webpage.

市場科  
現貨交易  
高級副總裁  
麥寶璇 謹啟

**Olivia Mak**  
**Senior Vice President**  
**Cash Trading**  
**Markets Division**

<sup>1</sup>所有參與者一般查詢熱線之通話可能會被錄音。請[按此](#)參閱香港交易所的私隱政策聲明。

All calls to and from the Participant General Enquiry Hotline may be recorded. HKEX Privacy Policy Statement is available [here](#).